Willis Investment Counsel buys $21,982,450 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Willis Investment Counsel scooped up 4,400 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 347,000 shares of Merck & Co. which is valued at $21,982,450.Merck & Co. makes up approximately 1.82% of Willis Investment Counsel’s portfolio.

Other Hedge Funds, Including , Bsw Wealth Partners boosted its stake in MRK in the latest quarter, The investment management firm added 2 additional shares and now holds a total of 4,935 shares of Merck & Co. which is valued at $312,632. Merck & Co. makes up approx 0.16% of Bsw Wealth Partners’s portfolio.Gemmer Asset Management reduced its stake in MRK by selling 433 shares or 14.23% in the most recent quarter. The Hedge Fund company now holds 2,609 shares of MRK which is valued at $153,461. Merck & Co. makes up approx 0.08% of Gemmer Asset Management’s portfolio.Horan Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 6,208 additional shares and now holds a total of 49,411 shares of Merck & Co. which is valued at $2,906,355. Merck & Co. makes up approx 0.77% of Horan Capital Management’s portfolio.Vigilant Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 1,496 shares of Merck & Co. which is valued at $87,950. Merck & Co. makes up approx 0.02% of Vigilant Capital Management’s portfolio.

Merck & Co. opened for trading at $63.71 and hit $63.88 on the upside on Tuesday, eventually ending the session at $63.58, with a gain of 0.05% or 0.03 points. The heightened volatility saw the trading volume jump to 57,98,353 shares. Company has a market cap of $175,812 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *